Bristol Myers Squibb FY2026 EPS Estimates Nudge Upward
Zacks Research marginally raised its full-year 2026 earnings forecast for Bristol Myers Squibb following a strong quarterly performance that exceeded consensus expectations.
Bristol Myers Squibb saw its full-year 2026 earnings per share estimates adjusted slightly upward by Zacks Research, as reported in data from GN markets/earnings. The analyst team now projects an EPS of $6.86 for the fiscal year, a marginal increase from their previous estimate of $6.85. This revision places the firm's individual forecast just below the broader consensus estimate of $6.95 per share for the same period.
The adjustment follows a robust quarterly report released on July 30, where the biopharmaceutical company significantly outperformed market expectations. Bristol Myers Squibb delivered EPS of $2.04, beating the consensus of $1.60 by $0.44, while generating revenue of $12.97 billion against an expected $11.74 billion. These results contributed to a net margin of 18.87% and a return on equity of 66.90%, with year-over-year revenue growth of 5.7%.
Quarterly Results Exceeded Consensus
The company's operational performance in the latest quarter highlighted strong profitability metrics. With a debt-to-equity ratio of 1.89 and a current ratio of 1.53, the firm maintains a stable balance sheet while achieving a beta of 0.23. The stock's market capitalization stands at $129.76 billion, with a price-to-earnings ratio of 13.99. Recent trading activity saw shares open at $63.52, fluctuating within a 52-week range between $42.52 and $68.64.
Forward Guidance and Dividend Policy
Bristol Myers Squibb has established its FY 2026 guidance at an EPS range of $6.75 to $7.00. The company recently declared a quarterly dividend of $0.63 per share, paid on August 3 to shareholders of record as of July 2. This translates to an annualized yield of 4.0% with a payout ratio of 55.51%. Zacks Research also provided longer-term projections, estimating FY 2027 EPS at $6.23 and FY 2028 EPS at $5.17, reflecting a gradual decline in per-share earnings over the next two years.
Analyst Ratings Remain Mixed
Market sentiment among institutional investors varies, with a consensus rating of Moderate Buy and a target price of $66.33. Royal Bank of Canada raised its price target to $64.00, while Wells Fargo set a target of $65.00. Conversely, UBS Group downgraded the stock from Buy to Neutral in August. Other actions include BMO Capital Markets maintaining a Market Perform rating and Raymond James initiating coverage with a Strong Buy recommendation. One senior vice president sold 500 shares in late August, retaining a position valued at approximately $1.14 million.
